FDA approves Mylan chemoprotective agent

Dexrazoxane for injection approved

PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for cancer patients.

Mylan announced Monday the approval of dexrazoxane for injection, a generic version of Pharmacia & Upjohn's Zinecard. The drug is a chemoprotective agent, used to protect healthy tissue from cancer drugs.

Various versions of the drug had sales of $3.4 million during the 12-month period ended in September, according to IMS Health.



Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

Login or Register to post a comment.